Table 1.

Clinical characteristics and previous treatment for all eligible patients

Stratum 1 (n = 44) n (%)Stratum 2 (n = 26) n (%)
Age at diagnosis (y)
    Median66.7
    Range0.2-17.90.6-15.5
Age at study entry (y)
    Median8.611.3
    Range0.4-20.22.4-18.6
Gender
    Male23 (52)20 (77)
    Female21 (48)6 (23)
Race
    Caucasian23 (52)20 (77)
    African-American11 (25)1 (4)
    Other10 (23)5 (19)
Histologic diagnoses
    Ependymoma14 (32)4 (15)
        Cellular6 (14)2 (7.5)
        Anaplastic8 (18)2 (7.5)
    High-grade glioma13 (30)3 (12)
        Glioblastoma6 (14)2 (8)
        AA2 (5)0 (0)
        Others5 (11)1 (4)
    Brainstem glioma9 (20)1 (4)
    Low-grade glioma7 (16)2 (8)
        JPA4 (9)1 (4)
        Others3 (7)1 (4)
    Medullo/PNET1 (2)16 (61.5)
        Medullo0 (0)10 (38.5)
        PNET1 (2)6 (23)
Performance score at study entry
    Median9085
    Range60-10060-100
Previous therapy
    Radiotherapy38 (86)26 (100)
    Chemotherapy42 (95)23 (88)
    Temozolomide and/or nitrosourea16 (36)7 (27)
  • NOTE: Two patients with primary spinal cord glioblastoma were enrolled on stratum 1 of this study.

    Abbreviations: AA, anaplastic astrocytoma; JPA, juvenile pilocytic astrocytoma; medullo, medulloblastoma; PNET, primitive neuroectodermal tumor.